RPG Life Sciences Ltd (RPGLIFE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by RPG Life Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026
Audio / Video · 31 Oct 2026, 3:09 am
RPG Life Sciences Releases Q2 FY27 Earnings Call Audio Recording RPG Life Sciences Limited has made the audio recording of its Q2 FY27 results earnings call available on its official website. The call, held on 30th Oct'26 at 5:00 p.m. IST, discussed the unaudited financial results for the quarter and half-year ended 30th Sep'26.
Investor Presentation
Investor Presentation · 30 Oct 2026, 4:54 am
RPG Life Sciences Reports Strong H1 FY27 Growth and API Expansion RPG Life Sciences reported a 16.2% YoY increase in revenue from operations to ₹407.3 cr for H1 FY27, with adjusted EBITDA rising 16.1% YoY to ₹97.9 cr (24.0% margin) and adjusted PAT growing 14.8% YoY to ₹62.9 cr. Segmentally, Domestic Formulations grew 13.0% YoY to ₹278.3 cr, International Formulations rose 7.0% YoY to ₹71.7 cr, and API surged 58.5% YoY to ₹54.6 cr. The company established dedicated subsidiary RPG Active Pharma, partnering with InvAscent with a ₹700 cr capital pool, and acquired Actis and Raghava Life Sciences.
Amendment to Policy on Related Party Transactions
Others (Uncategorized) · 30 Oct 2026, 3:49 am
RPG Life Sciences Reports Q2 FY27 Consolidated Financial Results RPG Life Sciences reported consolidated revenue from operations of Rs 211.64 cr for the quarter ended 30th Sep'26, up 16.5% YoY from Rs 181.68 cr and 8.2% QoQ from Rs 195.69 cr. Consolidated net profit for the quarter stood at Rs 28.22 cr, declining 23.4% YoY from Rs 36.85 cr primarily due to an exceptional gain of Rs 11.22 cr in the base quarter, while falling 7.7% QoQ. Consolidated H1 FY27 revenue reached Rs 407.33 cr, with net profit at Rs 58.79 cr.
Press Release
Press Release · 30 Oct 2026, 3:42 am
RPG Life Sciences Reports Strong Q2 FY27 Results With 16.5% Revenue Growth RPG Life Sciences reported a 16.5% YoY revenue growth to ₹211.6 crore for Q2 FY27 ended 30th Sep'26, crossing the ₹200 crore quarterly milestone. Adjusted EBITDA rose 15.0% YoY to ₹50.1 crore with a 23.7% margin, excluding ₹5.5 crore in one-off API acquisition and restructuring costs (reported EBITDA at ₹44.7 crore). Gross margin expanded 260 bps. Flagship brand Naprosyn surpassed ₹100 crore in sales. During the quarter, the company transferred its API unit to RPG Active Pharma and acquired Actis Generics and Raghava Lifesciences.
Outcome of Board Meeting held on October 29, 2026.
Outcome · 30 Oct 2026, 3:33 am
Financial Result for the quarter ended September 30, 2026
Financial Result · 30 Oct 2026, 3:15 am
Outcome of Board Meeting
Outcome · 30 Oct 2026, 3:08 am
Outcome of Board meeting
Outcome · 30 Oct 2026, 3:07 am
RPG Life Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) ■ Revenue: 21,164 (+16.5% YoY | +8.2% QoQ) ■ EBITDA: 4,042 (+3.6% YoY | -7.3% QoQ) ■ EBITDA Margin (%): 19.1 (-238 bps YoY | -318 bps QoQ) ■ PAT: 2,660 (-27.8% YoY | -13.0% QoQ) ■ EPS (INR): 17.1 (-23.4% YoY | -7.7% QoQ)
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and any other applicable provisions, please note the schedule of earnings call ....
Intimation · 30 Oct 2026, 5:00 pm
RPG Life Sciences Schedules Q2 FY27 Earnings Conference Call RPG Life Sciences Limited will host an earnings conference call on 30th Oct'26 at 5:00 PM IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26. The virtual group meeting is hosted in coordination with Dolat Capital Market Pvt. Ltd. and will be represented by Managing Director Ashok Nair and Chief Financial Officer Amol Lone. Dial-in access is available via universal numbers (+91 22 6280 1116 / +91 22 7115 8017) and international toll-free lines.
RPG Life Sciences Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation · 29 Oct 2026, 5:30 am
RPG Life Sciences Board Meeting Scheduled for 29th Oct'26 Financial Results RPG Life Sciences Limited has scheduled a Board of Directors meeting on 29th Oct'26 to consider, approve, and take on record the unaudited standalone and consolidated financial results along with the Limited Review Report for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities by designated persons and their relatives remains closed from 1st Oct'26 until 48 hours after the financial results are made public.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Clarus Capital I, Others
Acquisition/ Disposal of Shares · 28 Sept 2026, 7:43 pm
ChrysCapital Increases Stake in RPG Life Sciences to 7.04% Clarus Capital I acquired 37,463 equity shares (0.23% stake) of RPG Life Sciences Limited via open market purchases on 25th Sep'26. Consequently, the aggregate shareholding of the acquirers—Clarus Trust schemes managed by ChrysCapital Associates LLP—along with PAC ClearEdge LLC, rose from 11,26,278 shares (6.81%) to 11,63,741 shares (7.04%) of the total voting capital. Total equity share capital remains unchanged at Rs 13.23 crore comprising 1,65,39,015 equity shares of face value Rs 8 each.
Intimation for Scheme of Amalgamation of Actis Generics Private Limited and their respective shareholders under section 230 to 232 and other applicable provisions of the Companies Act, 2013.
Others (Uncategorized) · 26 Sept 2026, 5:46 am
RPG Life Sciences Announces Subsidiary Merger of Actis Generics into RPG Active Pharma RPG Life Sciences' subsidiary, RPG Active Pharma Limited (RPGAP; net worth INR 34.75 Cr as of 31st Mar'26), approved the amalgamation of its wholly owned subsidiary, Actis Generics Private Limited (net worth INR 34.60 Cr, FY26 revenue INR 45.96 Cr), into RPGAP under Sections 230–232 of the Companies Act, 2013. The merger involves no cash consideration or share issuance, as all Actis Generics shares will be cancelled. The move aims to streamline corporate structure, optimize capital, and enhance operational efficiencies without changing RPG Life Sciences' shareholding pattern.
update on share purchase agreement dated July 29, 2026 with Actis Generics Private Limited
Others (Uncategorized) · 25 Sept 2026, 3:06 am
RPG Life Sciences Completes 100% Acquisition of Actis Generics RPG Life Sciences Limited announced the completion of the acquisition of the entire stake in Actis Generics Private Limited on 24th Sep'26, pursuant to the Share Purchase Agreement executed on 29th Jul'26. The transaction was executed via RPG Active Pharma Limited (RPGAP). Consequently, effective 24th Sep'26, Actis Generics has become a wholly owned subsidiary of RPGAP and a subsidiary of RPG Life Sciences Limited.
Clarification for Volume Movement Letter
Others (Uncategorized) · 24 Sept 2026, 6:33 pm
RPG Life Sciences Clarifies Trading Volume Surge Driven Solely by Market Conditions RPG Life Sciences clarified to BSE on 24th Sep'26 that the recent surge in trading volume is purely market-driven. The company confirmed compliance with Regulation 30 of SEBI LODR Regulations, stating that all requisite disclosures have been made on time. Additionally, management affirmed there is no undisclosed, price-sensitive event, operational development, or announcement pending that would impact share price or trading volume.
The Exchange has sought clarification from RPG Life Sciences Ltd on September 24, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 24 Sept 2026, 5:43 pm
Intimation of Analysts/Institutional Investors Meet
Intimation · 17 Sept 2026, 10:38 pm
RPG Life Sciences to Attend Anand Rathi G-200 Summit RPG Life Sciences Limited will participate in the Anand Rathi G-200 Summit on 22nd Sep'26 in Mumbai. Scheduled from 10:00 AM IST onwards, the in-person event will encompass group meetings and one-on-one institutional investor interactions. The company confirmed that any discussions or investor presentations utilized during the summit will strictly align with information already available on the stock exchange and company websites.
Update on completion of BTA execution by RPG Active Pharma Limited with Raghava Life Sciences Private Limited
Others (Uncategorized) · 16 Sept 2026, 5:00 am
RPG Life Sciences Completes Acquisition of Raghava Life Sciences' API Business RPG Life Sciences announced that its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has completed the acquisition of the Active Pharmaceutical Ingredients (APIs) and intermediates business from Raghava Life Sciences Private Limited (RLSPL) via a slump sale as a going concern. Following the execution of the Business Transfer Agreement initially reported on 2nd Sep'26, the transfer of the API business is effective from 16th Sep'26.
update on Investment and Shareholders Agreement entered on July 29, 2026, subsidiary of the company allotted securities to the Investors.
Others (Uncategorized) · 10 Sept 2026, 4:20 am
RPG Life Sciences Completes ₹243.33 Crore Stake Sale in Subsidiary RPGAP RPG Life Sciences announced that its subsidiary, RPG Active Pharma Limited (RPGAP), allotted securities to India Life Sciences Fund IV Domestic and Vistaject Fund on 9th Sep'26. The transaction raised a total consideration of INR 243.33 crores, representing a 40% equity stake in RPGAP pursuant to the investment agreement dated 29th Jul'26. Following this allotment, RPGAP continues to operate as a subsidiary of RPG Life Sciences.
Update on Analyst/Institutional call
Others (Uncategorized) · 04 Sept 2026, 2:28 pm
Intimation of Investor meet dial in details
Intimation · 03 Sept 2026, 4:00 pm
Investors Presentation
Investor Presentation · 03 Sept 2026, 4:04 am
RPG Life Sciences' API Carve-Out, PE Partnership, and Twin Acquisitions RPG Life Sciences subsidiarized its API business into RPG Active Pharma (RPGAP). PE firm InvAscent is acquiring a 40% stake in RPGAP for ~INR 243.33 Cr. Concurrently, RPGAP announced two acquisitions: 100% of Actis Generics for ~INR 80 Cr and Raghava Life Sciences via a ~INR 135 Cr slump sale. These strategic transactions quadruple RPGAP's installed capacity across Vizag and Hyderabad, add ~INR 200 Cr in revenue potential, and strengthen its high-margin niche API portfolio while maintaining a zero-debt balance sheet.
Schedule of Investors Meet
Intimation · 03 Sept 2026, 4:00 am
RPG Life Sciences Schedules Short-Notice Analyst Call Following Strategic Announcement RPG Life Sciences will host a virtual investors and analysts group call on 3rd Sep'26 at 04:00 PM IST. The short-notice meeting follows a board meeting outcome and a strategic announcement made on 2nd Sep'26. Dial-in details and the corresponding investor presentation will be shared separately by the company.
Press Release
Press Release · 03 Sept 2026, 3:53 am
RPG Life Sciences Acquires Raghava Life's API Business for ₹135 Crore On 2nd Sep'26, RPG Life Sciences announced its subsidiary RPGAP will acquire Raghava Life Sciences’ API business for up to ₹135 crore via a slump sale. The deal adds an EU-GMP approved Hyderabad facility with 300 KL capacity, 22 commercialized APIs, and 7 pipeline assets. Following the Actis Generics buyout, this transaction accelerates RPGAP's buy-and-build strategy to bolster its integrated API scale, unlocking backward integration and cost synergies. The acquisition will be funded entirely through RPGAP’s recent equity raise.